Enliven Therapeutics, Inc.
ELVN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ELVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule kinase inhibitors, with lead programs in BCR-ABL and HER2, and has no approved products.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Enliven Therapeutics, Inc..
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule kinase inhibitors, with lead programs in BCR-ABL and HER2, and has no approved products.
- Enliven Therapeutics is a clinical-stage biopharmaceutical company with no products approved for commercial sale [sec_mda · as of 2025-03-13].
- As of June 30, 2026, the company reported cash and equivalents of $135.5M and a net loss of -$32.5M for the quarter [sec].
- The company is advancing its BCR-ABL program through clinical development and has made changes to its clinical development plan for ELVN-001 [sec_mda · as of 2026-08-05].
- Enliven has an automatic shelf registration allowing up to $200.0 million of common stock sales, with $40.0 million in gross proceeds received through June 30, 2026 [sec_mda · as of 2026-08-05].
- The company expects expenses and capital requirements to increase substantially as it advances its pipeline, including BCR-ABL and other small molecule research programs [sec_mda · as of 2026-08-05].
What works
- Enliven has a cash position of $135.5M as of June 30, 2026, providing a runway to fund ongoing clinical development [sec].
- The company has access to up to $200.0 million in additional capital through its automatic shelf registration, with $40.0 million already raised [sec_mda · as of 2026-08-05].
- The BCR-ABL program is advancing through clinical development, indicating progress in the pipeline [sec_mda · as of 2026-08-05].
What to weigh
- Enliven has a limited operating history and no products approved for commercial sale, making it difficult to evaluate its likelihood of success [sec_mda · as of 2025-03-13].
- The company has incurred net losses, with a net loss of -$32.5M for the quarter ended June 30, 2026, and expects losses to continue [sec].
- Expenses and capital requirements are expected to increase substantially, and the company may need additional capital, which if unavailable could force delays or reductions in programs [sec_mda · as of 2026-08-05].
- The company decided not to develop the HER2 program beyond 2025, narrowing its pipeline [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
The company has no approved products and is early in development.
“We are early in our development efforts, with a limited operating history, and we have no products approved for commercial sale”
SEC MD&A · March 13, 2025
The company expects expenses to increase as it advances its BCR-ABL program.
“We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities, if and as we: • advance our BCR-ABL program through clinical development;”
SEC MD&A · August 5, 2026
The company has access to up to $200 million in common stock sales.
“there was $200.0 million of our common stock available for sale under the Sales Agreement”
SEC MD&A · August 5, 2026
The company decided not to develop the HER2 program beyond 2025.
“incur costs related to our decision not to develop the HER2 program beyond 2025”
SEC MD&A · November 12, 2025
Risks & what to watch (4)›
Key risks
- No approved products — Enliven has no products approved for commercial sale, with a limited operating history [sec_mda · as of 2025-03-13].
- Need for additional capital — The company expects increasing expenses and may need additional capital; if unavailable, it could delay or reduce programs [sec_mda · as of 2026-08-05].
- HER2 program discontinued — The company decided not to develop the HER2 program beyond 2025, narrowing its pipeline [sec_mda · as of 2025-11-12].
- Clinical development risks — As a clinical-stage company, Enliven faces risks of unforeseen expenses, delays, and complications in development [sec_mda · as of 2024-11-13].
What to watch
- Progress and updates from the BCR-ABL program clinical development [sec_mda · as of 2026-08-05].
- Changes to the clinical development plan for ELVN-001 [sec_mda · as of 2026-08-05].
- Capital raising activities under the $200 million shelf registration [sec_mda · as of 2026-08-05].
- Financial results and cash runway updates in future quarterly reports [sec].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Enliven Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Enliven Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
139.4 months
D/E 0.02 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
0 buys · 43 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
171
Total value held
$2.24B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 7,959,538 | $312.0M |
| fmr llc | 6,829,246 | $267.7M |
| polar capital holdings plc | 5,065,933 | $198.6M |
| blackrock, inc. | 3,684,707 | $144.4M |
| commodore capital lp | 3,275,000 | $128.4M |
| vanguard capital management llc | 2,168,162 | $85.0M |
| citadel advisors llc | 1,871,515 | $73.4M |
| venrock adviser, llc | 1,726,331 | $67.7M |
| novo holdings a/s | 1,280,000 | $50.2M |
| state street corp | 1,091,106 | $42.8M |
Showing top 10 of 171 institutional holders of Enliven Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 12.8%
- Days to cover
- 3.0
- Shares short
- 5,374,014
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule kinase inhibitors, with lead programs in BCR-ABL and HER2, and has no approved products.
What is Enliven Therapeutics, Inc.'s lead drug candidate?
Enliven Therapeutics, Inc.'s most advanced tracked candidate is elvn-001 (Phase 1) for CML (Chronic Myelogenous Leukemia); Chronic Myeloid Leukemia.
Who is the CEO of Enliven Therapeutics, Inc.?
Mr. Richard A. Fair M.B.A. is the chief executive officer of Enliven Therapeutics, Inc. (ELVN).
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc. (ELVN) is headquartered in Boulder, CO, United States.
What therapeutic areas does Enliven Therapeutics, Inc. focus on?
Enliven Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.